These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3434494)

  • 21. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
    Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
    J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
    Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
    Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
    Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
    El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
    Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
    Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
    Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response criteria in research protocols for prostatic cancer.
    Akaza H
    Prog Clin Biol Res; 1990; 357():85-95. PubMed ID: 2217483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical study of RU 23908 (nilutamide) in prostatic cancer].
    Akaza H; Aso Y; Niijima T; Fuse H; Izaka S; Akimoto S; Shimazaki J; Imai K; Yamanaka H; Kihara K
    Hinyokika Kiyo; 1991 Apr; 37(4):407-20. PubMed ID: 1892002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
    Citrin DL; Elson P; DeWys WD
    Cancer; 1984 Jul; 54(1):13-7. PubMed ID: 6372984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer.
    Slack NH; Mittelman A; Brady MF; Murphy GP
    Cancer; 1980 Dec; 46(11):2393-402. PubMed ID: 7002280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy of solid tumors.
    Petersen M; Taylor JD
    Med J Aust; 1978 Mar; 1(6):340. PubMed ID: 661705
    [No Abstract]   [Full Text] [Related]  

  • 33. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma.
    Eisenberger MA; Bezerdjian L; Kalash S
    Urol Clin North Am; 1987 Nov; 14(4):695-706. PubMed ID: 3314063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer: evaluation of response to treatment, response criteria, and the need for standardization of the reporting of results.
    Aabo K
    Eur J Cancer Clin Oncol; 1987 Feb; 23(2):231-6. PubMed ID: 3327696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in nail pigment with cancer chmotherapy.
    Nixon DW
    Arch Intern Med; 1976 Oct; 136(10):1117-8. PubMed ID: 987759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melphalan in metastatic cancer of the prostate: a pilot study.
    Franks CR
    Cancer Treat Rep; 1979 Feb; 63(2):228-9. PubMed ID: 445500
    [No Abstract]   [Full Text] [Related]  

  • 37. Editorial: New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer.
    Festuccia C; Negri-Cesi P; Gravina GL
    Curr Drug Targets; 2016; 17(3):254-6. PubMed ID: 26876024
    [No Abstract]   [Full Text] [Related]  

  • 38. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate.
    Berry WR; Laszlo J; Cox E; Walker A; Paulson D
    Cancer; 1979 Aug; 44(2):763-75. PubMed ID: 476583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Objective response criteria in prostate cancer.
    Akaza H; Jones WG; Javadpour N; van Oosterom AT; Isaka S; Shimazaki J
    Prog Clin Biol Res; 1990; 357():193-7. PubMed ID: 2217463
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer.
    Wilding G; Grindey G; Munshi N; Seitz D; Einhorn L
    Invest New Drugs; 1993; 11(2-3):203-5. PubMed ID: 8262732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.